#ASH17: Become Trend on twitter at (2017-12-13 01:40)


People talking about #ASH17: - Merck - JanssenUS - bmsnews - weluvdogs53 - chadinabhan - fkerbauy - DrRaulCordoba - lormarmar - HaniHashmi - szusmani[...]
- raballesterosr - TuftsB - Mohty_EBMT - DrOmarNadeem - con_forme - dehought - Wowbagger23 - NVHemophilia - Mohty_EBMT - Mohty_EBMT - raballesterosr - Mohty_EBMT - Mohty_EBMT - marrow - Mohty_EBMT - LucaFields - DrRaulCordoba - Mohty_EBMT - tx_rockstar - Barbara77051620 - DrAnasYounes - biotech_seel - chadinabhan - Mohty_EBMT - Mohty_EBMT - drkomanduri - IrinaBrooke1 - DrJohnSuh - tarsheen2 - JustinArnallUNC - sjill32 - sjill32 - dgermain21 - sjill32 - markxevans - mana1981 - OncLiveSOSS - Mohty_EBMT - aidole - Mohty_EBMT - JustinJorgensen - BioWorld - TheDawnBell - jeliliojodu - Mohty_EBMT - CllSociety - CllSociety - PGregoey - RupeshPophale - CllSociety - MedscapePharm - drKamarajk - ahighelevation - CllSociety - CllSociety - jonathonbcohen - theMMRF - NCICCR_Lymphoma - MattKalaycioMD - Catinker - DarlonDario - SusanDFCI - RenoHemonc - MVAS52 - UNeoFellow - kariusdx - guiperini - JMongeMD - surveyist - Amgen - itsthebunk - DrRaulCordoba - DrRaulCordoba - JHughesPharmD - nicolelynnann - johnran28545123 - BrayLovisa - JMongeMD - Gupta_Calling - Alixpeasoup - Olderpreneurs - pharmamaven - AnticoagNet - BloodyKleio - Candy001122 - Buzzing_09 - Buzzing_09 - MichaelodwyerMD - marinamartello - grpetersen1

This Tag appearing in: United States: ( Memphis - ).
Popular tweets tagged with #ASH17:
#ASH17 Mohamad Mohty @Mohty_EBMTπŸ” Watch out for this new player #ASH17 @myelomaMD @GSK @GSKUS @Mohty_EBMT
loading...
#ASH17 Mohamad Mohty @Mohty_EBMTπŸ” Thank you @ASH_hematology - until next year - Homeward Bound #ASH17 #MMSM
#ASH17 Raul Cordoba @DrRaulCordobaπŸ”On my way home 🏑πŸ‡ͺπŸ‡Έ from #ASH17 #Atlanta
#ASH17 Mohamad Mohty @Mohty_EBMTπŸ” Late-Breaking Abstracts Session at #ASH17
NHFNevada @NVHemophiliaπŸ” Looking for an easy way to explain hemophilia? Share our two-minute video. #ASH17
#ASH17 Saad Usmani @szusmaniπŸ” After freezing at #ASH17, I’m happy #ASH18 will be in sunny California!
#ASH17 Raul Cordoba @DrRaulCordobaπŸ” ASH welcomes @DrAlexisThompsn of @NUFeinbergMed as 2018 ASH president #ASH17
#ASH17 maris lopez @weluvdogs53πŸ” PMBCL makes up approximately 2-4% of all #NonHodgkinLymphoma cases. #ASH17
Merck @MerckDid you know approximately every 3 minutes someone in the U.S. is diagnosed with ? πŸ”//twitter.com/i/web/status/940310245443883008" target="_blank">twitter.com
JanssenUS @JanssenUSπŸ”Treatment innovation takes on another meaning at Oncology. At the core of our research presented at is the move tow twitter.com ard cancer interception. See here for insights from Yusri Elsayed
Bristol-Myers Squibb @bmsnewsπŸ”TWITTER QUIZ: With a yearly incidence rate of more than 385,000, which type of Lymphoma is the most common? #ASH17
chadi nabhan MD, MBA @chadinabhanπŸ”This poster was presented . Manuscript under review. twitter.com
Fabio R. Kerbauy, MD @fkerbauyπŸ”Brazilian lymphoma perspective on :

1. A+AVD very far from reality for us so far ($$$)
2. We should probably do R-maintenance since no good salvage in FL. G is $?
3. Benda is arriving: prepare infections?
4. We need Lena. Right now.
5. God bless R-CHOP.


maria marquez @lormarmarπŸ”Interesting discussion regarding cellular therapies in the post-transplant relapsed setting
Hani Al-Hashmi @HaniHashmiπŸ”Original Article: Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma nej.md
Bob Tufts @TuftsBπŸ”Predictions for the future ASH meetings. (counting unfollowers, 3, 2, 1 πŸ’£)
Omar Nadeem, MD @DrOmarNadeemπŸ”#ASH17 was great with many practice altering studies and even more promise/hope for the future #progress
armand @con_formeπŸ”ASH17: J&J's Darzalex delivers combo win biopharmadive.com #ash17
Damon Houghton @dehoughtπŸ”Thanks to and for hosting us at this weekend. Next up: @SDConventionCt in for !
Hieflo @Wowbagger23πŸ”Chadi, I am sorry I had not seen your poster at . You have a link for download which is still active? I would appreci twitter.com ate to see!
Mohamad Mohty @Mohty_EBMTπŸ” has been a positively inspirational meeting. I have said this before, and this meeting strengthened it-this is truly the most exciting time to practice . Looking forward to getting back to clinic!
Mohamad Mohty @Mohty_EBMTπŸ” In case you missed it, #ASH17 Education & Scientific Sessions will be available on ASH On Demand ashondemand.org
Jeff Szer @marrowπŸ”Qantas is a full service airline. Check out the magazine rack in first class boarding QF8 to Sydney from Dallas Fort twitter.com Worth. They truly cater to all requirements.
Mohamad Mohty @Mohty_EBMTπŸ”I want everyone who presents CAR-T data to present data this way
This is an estimate of Tisagenlecleucil based on ODAC & a press release
Luca Field's @LucaFieldsπŸ”Last Call! Hematologists liked to play fast and loose with the abstract submission deadline...
Mohamad Mohty @Mohty_EBMTπŸ”Good bye Atlanta . We can say it was a successful meeting but the weather not so much πŸŒ¨β„οΈβ˜ƒοΈβ˜”οΈ Anyway, Merry Christmas & Happy 2018. Everyone of us deserves it.
transplantrockstar @tx_rockstarπŸ”It was reported at that the frontline combination of atezolizumab, obinutuzumab, and bendamustine, achieved a complete response in 75% of patients with follicular lymphoma
Anas Younes, M.D. @DrAnasYounesπŸ”The latest Science, Health & Cancer News Daily! paper.li Thanks to @ASCOPost #endcancer #ash17
Seel @biotech_seelπŸ”New personalized prediction model uses genomic data to risk stratify patients with myelodysplastic syndromes.
chadi nabhan MD, MBA @chadinabhanπŸ”We had a poster at and a letter under review on post marketing studies after accelerated approvals. twitter.com
Mohamad Mohty @Mohty_EBMTπŸ”@Dalonsoescolano Another std of care Dara-vmp (Dara-vcd) that will have a good future #ASH17 @Mohty_EBMT
Krishna Komanduri @drkomanduriπŸ”Update of ZUMA-1 data from #ASH17 via @ASHClinicalNews. #lymphoma #tcellrx ashclinicalnews.org
Mutant Strong @IrinaBrooke1πŸ” featured news on promising advances in the treatment of . Check out our latest blog for our meeting recap.
John Suh @DrJohnSuhπŸ”Alok A. Khorana, MD, on The Costs of VTE in Cancer Patients: Expert Perspective ascopost.com
Tarsheen Sethi, MD @tarsheen2πŸ”Clinically relevant/important data presented by at on therapy & outcomes POST-checkpoint inhibitor therapy in
Jill Harrison @sjill32πŸ”Isn't it nice that a patient can be an "Influencer" at a medical conference? The Power of Twitter.
Jill Harrison @sjill32πŸ”Thanks to all who presented, attended, and followed the 2017 ASH Annual Meeting! We hope you enjoyed
markxevans @markxevansπŸ”The latest The markxevans Daily! paper.li #ash17
OncLive SOSS @OncLiveSOSSπŸ”We're headed to San Francisco this weekend! Join us for the State of the Science Summit on Hematologic Malignancies a twitter.com nd recap
Elodia Resendez @aidoleπŸ” Prevention and early detection could lower the risks for cancer patients developing VTE. #ASH17 cards.twitter.com
loading...
Mohamad Mohty @Mohty_EBMTπŸ”Top Influencers of πŸ‘‰ via
Mohamad Mohty @Mohty_EBMTπŸ” One of my favorite #ASH17 abstracts. Read on @myelomacrowd @grpetersen1 @AhlstromJenny @MayoMyeloma myelomacrowd.org
CLL Society Inc. @CllSocietyπŸ”I'm Dr. Brian Koffman & I'll be taking over this handle for the next few hours to discuss hematology at –Dr.K (Paid Consultant)
CLL Society Inc. @CllSocietyπŸ”As a physician & CLL patient, is an important opportunity to learn about potential new advancements in CLL–Dr. K (Paid Consultant)
Patrice Gregory @PGregoeyπŸ” New research is offering hope for symptomatic relief in patients with myelofibrosis. #ASH17 cards.twitter.com
Rupesh Pophale @RupeshPophaleπŸ” #ASH17 is wrapping up today. Thank you @ASH_hematology for hosting. We look forward to next year.
CLL Society Inc. @CllSocietyπŸ”I'm looking forward to hearing from cancer researchers around the world about the latest studies in CLL –Dr. K (Paid Consultant)
Medscape Pharmacists @MedscapePharmπŸ”Emicizumab, approved for hemophilia A with factor VIII inhibitors, has been hailed as a game changer: ms.spr.ly #ASH17
CLL Society Inc. @CllSocietyπŸ”Thanks to our experts & all who tuned in to our takeover. Check back for more updates throughout the meeting
CLL Society Inc. @CllSocietyπŸ”Chimeric Antigen Receptor (CAR) T-Cell Therapy Explained By John Pagel & in
Jonathon Cohen MD MS @jonathonbcohenπŸ” You've been quoted: "Dr. John Leonard Leads Global Lymphoma Conversation with "
Multiple Myeloma RF @theMMRFπŸ”. presented awards in appreciation for clinical Innovation, Collaboration, and Acceleration to our MMRC sites at . Re twitter.com ad about our award winners here:


CCR Lymphoma @NCICCR_LymphomaπŸ”Collins Conclusions no.3:
ctDNA promising for a number of indications
- tumour burden (level correlates with MTV)
- prognosis (rapid reduction assoc with good prog)
- diagnosis
- guide treatment (identify drugable mutations)
More testing needed however.

Matt Kalaycio, MD @MattKalaycioMDπŸ”Poor hasn’t found a way to both present in Spotlight Session and simultaneously tweet. So I’m tweeting these images of him and his nice overview of path to HCT.
Cheryl Tinker @CatinkerπŸ”Today is the last day of . Thank you to all the healthcare providers in attendance & around the world for your work battling .
Dario Londono @DarlonDarioπŸ”Original Article: Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism nej.md
Susan Ehret @SusanDFCIπŸ”More than 30 Dana-Farber researchers presented at . Review highlights from the meeting here: ms.spr.ly
Santhosh Ambika @RenoHemoncπŸ” Goodell: epigenetic regulators, such as DNMT3A, amongst most frequently mutated in MDS/AML. DNMT3A loss immortalizes HSC.
MV @MVAS52πŸ” take note of 's comments at (note 5 - vs CAR-T Approaches) as they could be after you

UNeonatologyFellow @UNeoFellowπŸ”Time well spent away from ASH2017 in Atlanta! Powerful experience at the National Center for Civil and Human Rights.
Guilherme Perini, MD @guiperiniπŸ”Brazilian lymphoma perspective on :

1. A+AVD very far from reality for us so far ($$$)
2. We should probably do R-ma twitter.com intenance since no good salvage in FL. G is $?
3. Benda is arriving: prepare infections?
4. We need Lena. Right now.
5. God bless R-CHOP.


Jorge Monge, M.D. @JMongeMDπŸ”A CAR-T to cure CD19 CAR-T related B cell aplasia. poster 4463.

A CAR-T to kill CAR-Ts.


surveyist @surveyistπŸ” Weyrich: Caplacizumab, a nanobody that blocks VWF-plt binding, effectively treats TTP leading to rapid normalization of plt count
Amgen @AmgenπŸ”MRD testing may help predict relapse in #bloodcancer. #ASH17 #AmgenOnco
Liza Bernstein @itsthebunkπŸ”Great visualization of in the healthcare conversation. Let’s keep this going.
Raul Cordoba @DrRaulCordobaπŸ”I will never forget in as it was my first time where I participated as a speaker at in the Scientific Symposium o twitter.com n and thanks to and
Lovisa Bray @BrayLovisaπŸ” We show 4 yr survival rate of 82.3% in newly diagnosed myeloma, age <=65, eligible for SCT treated confirming survival results seen in IFM 2009 trial. Trial populations often have selection biases. So we are glad that the results are generalizable
Jorge Monge, M.D. @JMongeMDπŸ”β€œOne of the great success stories of pediatric oncology” curing most patients with ALL
vnmaster gupta @Gupta_CallingπŸ” "Data on ex vivo CRISPR/Cas9 genome-edited human hematopoietic stem cells shows increased production of fetal hemog twitter.com lobin; Approximately 80-95 percent editing was achieved in CD34+ cells" New, Robust Genome Editing Data for Sickle Cell Disease at the ASH
Alix @AlixpeasoupπŸ” : CAR-T Wallops Blood Cancer , , , , ,
Anticoag.net @AnticoagNetπŸ”Biggest prospective evidence to date examining DOACs vs. LMWH for cancer-associated VTE. Reduced VTE recurrence, but twitter.com increased major bleeding with edoxaban....Will need to digest and dissect further.
Jo Brown @Buzzing_09πŸ” Merck's Keytruda picks up FDA priority review in non-Hodgkin lymphoma $MRK #ASH17 fiercepharma.com
Jo Brown @Buzzing_09πŸ” AbbVie, Roche's Venclexta combination superior to chemotherapy in CLL: study firstwordpharma.com $ABBV $RHHBY #ASH17
Michael O'Dwyer @MichaelodwyerMDπŸ”@MaverickNY Good catching up @MaverickNY at #ASH17 . Our CML days seem like another world!
Marina Martello @marinamartelloπŸ” If you are a myeloma cell winter is coming: the night is dark and full of car-t cells #ash17
Surviving Myeloma @grpetersen1πŸ” - Thank You to all myeloma specialists who attended ASH, or follows it closely! The science is moving SO FAST. twitter.com

05

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive